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AbsTrACT
background X- linked ichthyosis (Xli) is an uncommon 
dermatological condition resulting from a deficiency 
of the enzyme steroid sulfatase (sTs), often caused 
by X- linked deletions spanning STS. some medical 
comorbidities have been identified in Xli cases, but small 
samples of relatively young patients has limited this. 
STS is highly expressed in subcortical brain structures, 
and males with Xli and female deletion carriers appear 
at increased risk of developmental/mood disorders 
and associated traits; the neurocognitive basis of these 
findings has not been examined.
Methods Using the UK Biobank resource, comprising 
participants aged 40–69 years recruited from the 
general UK population, we compared multiple medical/
neurobehavioural phenotypes in males (n=86) and 
females (n=312) carrying genetic deletions spanning STS 
(0.8–2.5 Mb) (cases) to male (n=190 577) and female 
(n=277 862) non- carrier controls.
results We identified an elevated rate of atrial 
fibrillation/flutter in male deletion carriers (10.5% vs 
2.7% in male controls, Benjamini- hochberg corrected 
p=0.009), and increased rates of mental distress 
(p=0.003), irritability (p<0.001) and depressive- anxiety 
traits (p<0.05) in male deletion carriers relative to male 
controls completing the Mental health Questionnaire. 
While academic attainment was unaffected, male and 
female deletion carriers exhibited impaired performance 
on the Fluid intelligence Test (cohen’s d≤0.05, corrected 
p<0.1). neuroanatomical analysis in female deletion 
carriers indicated reduced right putamen and left nucleus 
accumbens volumes (cohen’s d≤0.26, corrected p<0.1).
Conclusion adult males with Xli disease- causing 
deletions are apparently at increased risk of cardiac 
arrhythmias and self- reported mood problems; altered 
basal ganglia structure may underlie altered function and 
Xli- associated psychiatric/behavioural phenotypes. These 
results provide information for genetic counselling of 
deletion- carrying individuals and reinforce the need for 
multidisciplinary medical care.
InTroduCTIon
X- linked ichthyosis (XLI (OMIM: 308100)) is an 
uncommon dermatological condition character-
ised by the presence of large dark- brown scales,1 
although much milder skin phenotypes have been 
reported2; it occurs due to deficiency of the enzyme 
steroid sulfatase (STS), encoded by the X- linked 
STS gene (OMIM: 300747). STS cleaves sulfate 
groups from steroid hormones (eg, dehydroe-
piandrosterone sulfate (DHEAS)) altering their 
solubility/activity; the XLI- associated skin pheno-
type arises from cholesterol sulfate accumulation 
in the stratum corneum. 80-90% of XLI cases are 
caused by complete/partial deletion of STS, with 
remaining cases attributable to STS point muta-
tion(s); the typical deletion (~1.5 Mb) encompasses 
STS and a small number of adjacent genes.3 In 
~85% of cases, the mutation is transmitted from 
unaffected (or mildly affected) carrier mothers, and 
in the remainder it occurs de novo during parental 
gametogenesis.4
Several extracutaneous comorbidities have 
been reported in individuals possessing XLI- 
associated mutations: a) benign corneal opacities 
affect ~10%–50% of males with XLI and ~25% 
of female carriers,1 b) ~20% of males with XLI 
have cryptorchidism; an associated risk of testic-
ular germ cell cancer is less clear and supported 
by a few case reports1 5 and c) delayed/prolonged 
labour affects ~60% of female carriers.1 6 Occa-
sional comorbidities include: pyloric hypertrophy, 
congenital defect of the abdominal wall, acute 
lymphoblastic leukaemia, bilateral periventricular 
nodular heterotopia and end- stage renal failure.1 
Rare, larger genetic deletions which can include 
NLGN4X and KAL are associated with a number 
of neurological conditions such as epilepsy, intel-
lectual disability, autism and anosmia, and contig-
uous gene syndromes including Rud, Conradi and 
Kallman syndromes.1 3 To date, samples of patients 
with XLI and carrier females have been relatively 
small/superficially phenotyped, and larger- scale 
studies may reveal hitherto unappreciated comor-
bidities with implications for morbidity/mortality.
STS is expressed in the developing and adult 
human brain (with highest expression in subcortical 
structures7 8) and may therefore influence neurode-
velopment. Boys with XLI are at elevated risk of 
developing attention deficit hyperactivity disorder 
(ADHD) and motor problems,3 9 10 and also poten-
tially early onset psychosis.11 We have previously 
shown that males with XLI exhibit higher rates of 
inattention, impulsivity (but not motor impulsivity), 
mood problems, disruptive behaviour and autism- 
related traits, and are more likely to be diagnosed 
with developmental conditions (including ADHD/
autism) and mood disorders, when compared with 
males from the general population.12 A study of 
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female carriers revealed a comparable suite of behavioural differ-
ences from control subjects, together with an increased likeli-
hood of postpartum depression.6 The pattern of behavioural 
phenotypes seen in males with XLI/carrier females overlaps with 
that seen in STS- deficient mice,13–17 and may therefore be largely 
ascribed to biological effects of STS deficiency rather than ascer-
tainment or socialisation effects. Previous behavioural pheno-
typing approaches in XLI have been suboptimal: a) survey- based 
studies did not collect genetic data and so could not objectively 
confirm or define STS deletion carrier status, and these studies 
may theoretically have elicited responses from more severely 
affected individuals inflating risk estimates, b) only relatively 
early age points have been assessed (average age <45 years) and 
c) studies have had either no control group, or no contempora-
neously recruited control group. No study has yet investigated 
the cognitive or neurobiological basis of behavioural phenotypes 
in XLI. To address these limitations/knowledge gaps, here we 
use the power of the UK Biobank, a large, accessible resource 
comprising extensively phenotyped and genotyped members 
of the population of the UK,18 to compare medical/medica-
tion history, objective/self- reported behavioural/mental health 
measures, cognition and subcortical neuroanatomy between 
males and females carrying deletions most commonly seen in 
XLI and sex- matched non- carrier controls.
MeThods
Participants
Participants were individuals (aged 40–69 years) recruited under 
UK Biobank informed consent procedures between 2006-2010, 
for which anonymised genotype/phenotype data were available.19
CnV calling
Anonymised genotype data were downloaded as raw (CEL) 
files from the UK Biobank website,19 stored on a secure Linux 
server and analysed with UNIX- based commands. Affymetrix 
Power Tools (APT) software20 was used to generate normalised 
signal intensity data, genotype calls and confidences. This argu-
ment incorporated genotypic sex data downloaded from the UK 
Biobank website, and compared with sex data generated through 
PennCNV- Affy software.21 Approximately 750 000 biallelic 
markers were analysed through PennCNV- Affy to process cluster 
plots. Canonical genotype clusters, Log R ratios and B allele 
frequencies were generated to complete the PennCNV recom-
mended process for CNV calls. Individuals with deletions of 
0.8–2.5 Mb spanning STS were identified, with calls and coordi-
nates based on the GRCh37/hg19 genome build; this range was 
selected to reflect the majority of XLI cases, to facilitate robust 
CNV calling, and to exclude individuals with multiple complex 
medical issues arising from large contiguous gene deletions. 
Following QC, CNV data were available for a total of 468 837 
individuals.
Measures
Hospital diagnoses according to the International Statistical 
Classification of Diseases and Related Health Problems Revi-
sion-10 (ICD-10),22 self- reported non- cancer illnesses, relevant 
questions from the Mental Health Questionnaire (MHQ)23 and 
medication history were analysed. Highest levels of academic 
qualification and key performance measures on seven cognitive 
tasks (transformed and converted to z- scores as described previ-
ously24) were also analysed: number of incorrect matches on the 
Pairs Matching Test (episodic memory), mean time to correctly 
identify matches in the Reaction Time Task (simple processing 
speed), total number of correct answers in the 13- question 
Fluid Intelligence Test (reasoning/problem- solving),25 maximum 
number of digits remembered in the ‘Digit Span’ task (numeric 
working memory), number of correct substitutions in a Symbol 
Digit Substitution Test (complex processing speed) and time to 
complete two variants of the Trail Making Task (visual atten-
tion). Brain images were acquired using Siemens Skyra 3T scan-
ners in UK Biobank’s imaging centres in Cheadle and Newcastle, 
UK using identical acquisition protocols26; T1- weighted brain 
images were processed using automated methods implemented 
in FreeSurfer27 to obtain volumetric estimates for eight right and 
left subcortical regions.
statistics
Data were analysed using SPSS V.25.0 (IBM). As male and female 
deletion phenotypes could differ in magnitude and/or nature, 
two comparisons were performed: male deletion carriers versus 
male non- carriers, and female deletion carriers versus female 
non- carriers. Across the overall sample for each cognitive/neuro-
imaging measure, outlying values >2.2 times the IQR below 
the first quartile, or above the third quartile, were excluded.28 
Categorical data were analysed using χ2 test (continuity- adjusted 
for 2×2 analyses)/Fisher’s exact test, with ORs and 95% CIs 
presented as a measure of effect size. Normally distributed data 
were compared using unpaired t- test. Ordinal/non- normally 
distributed data, and small datasets (<30 participants), were 
compared using Mann- Whitney U test, with Cohen’s d presented 
as a measure of effect size.29 For cognitive analyses with sample 
sizes >30, hierarchical linear regression controlling for age was 
performed.24 Data are presented as median values (with 95% 
CIs) or mean±SE of the mean. Two- sided p values <0.05 were 
regarded as nominally significant, with p values <0.1 after 
Benjamini- Hochberg adjustment30 regarded as surviving correc-
tion for multiple comparisons.
resulTs
Identification and characterisation of deletion cases
We identified 86 male and 312 female deletion carriers, and 
190 577 male and 277 862 female non- carriers, giving deletion 
rates of ~1/2200 in males and ~1/890 in females. The mean dele-
tion size was 1.60±0.01 Mb from ChrX:6 487 716–8 087 815, 
encompassing the PUDP/HDHD1 (OMIM: 306480), STS, VCX 
(OMIM: 300229) and PNPLA4 (OMIM: 300102) genes and 
the MIR4767 microRNA. Male deletion subjects did not differ 
significantly from male controls in terms of age (58.0±0.8 vs 
57.1±0.02 years,  respectively,  t[190 606]=−0.999,  p=0.318); 
the ages of female deletion subjects and female controls were 
also equivalent (56.3±0.5 vs 56.7±0.02 years, respectively, 
t[228 024]=0.736, p=0.461).
ICd-10 diagnoses
Nine ICD-10 unique descriptive codes were present in >2500 
males overall and >2.5% of male deletion subjects, of which 
two were significantly more common in male deletion carriers 
than in control males (online supplementary table 1): ‘atrial 
fibrillation/flutter’ (10.5% vs 2.7%, OR 4.2 (95% CI 2.1 to 
8.3), p=0.001) and ‘skin of other and unspecified parts of face’ 
(5.8% vs 1.5%, OR 4.0 (95% CI 1.6 to 9.9), p=0.01); while 
these p values would not survive stringent multiple compar-
ison testing taking into account all possible ICD-10 codes, they 
did survive multiple comparison testing across the nine afore-
mentioned codes (corrected p=0.009 and 0.045, respectively). 
Ten ICD-10 unique descriptive codes were present in >2500 
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Table 1 Frequency of mental distress, help- seeking behaviour and psychiatric illness in male and female deletion carriers and controls completing 
the mental health questionnaire
Measure Male control Male deletion
statistical 
analysis Female control
Female 
deletion
statistical 
analysis
Ever suffered mental distress preventing usual 
activities? (Yes/No)
15 068 (26%)/42 882 (74%) 12 (57%)/9 (43%) χ2[1]=9.02, 
p=0.003
29 250/46 323 30/63 χ2[1]=1.37, 
p=0.242
Ever sought or received help for mental distress? 
(Yes/No)
17 522/41 137 7/14 χ2[1]=0.01, 
p=0.914
35 122/41 035 39/56 χ2[1]=0.786, 
p=0.375
Social anxiety or social phobia (Yes/No) 756/58 099 0/21 P>0.99 892/75 547 1/94 P>0.99
Phobia (other than social or agoraphobia) (Yes/No) 576/58 279 1/20 P=0.187 1256/75 183 2/93 P=0.671
Panic attacks (Yes/No) 2266/56 589 1/20 P=0.562 5197/71 242 6/89 χ2[1]=0.000, 
p>0.99
Obsessive compulsive disorder (Yes/No) 329/58 526 1/20 P=0.111 508/75 931 0/95 P>0.99
Depression (Yes/No) 9188/49 667 6/15 P=0.125 19587/56 852 24/71 χ2[1]=0.000, 
p>0.99
Anxiety, nerves or generalised anxiety disorder (Yes/
No)
6287/52 568 3/18 P=0.486 12889/63 550 16/79 χ2[1]=0.000, 
p>0.99
females overall and >2.5% of female deletion subjects, none of 
which were significantly more common in deletion than control 
subjects (online supplementary table 2). Diagnosis rates of devel-
opmental and mood/anxiety disorders did not differ between 
male and female deletion and control subjects, although base-
line rates of each were very low across groups (<0.5%) (online 
supplementary tables 3 and 4).
self-reported non-cancer illnesses
We compared rates of self- reported non- cancer physical/mental 
illnesses of interest based on the ICD-10 findings above, or 
previous literature, across groups (online supplementary tables 
5 and 6). Compared with male controls, male deletion cases 
reported a significantly higher prevalence of blistering/desqua-
mating skin disorder (4.7% vs 0.2%, OR 28.6 (95% CI 10.4 to 
78.4), corrected p<0.020) and allergy/hypersensitivity/anaphy-
laxis (4.7% vs 0.5%, OR 9.1 (95% CI 3.3 to 24.9), corrected 
p=0.020), and a nominally significantly increased rate of heart 
arrhythmia (3.5% vs 0.6%, OR 5.9 (95% CI 1.9 to 18.6), 
p=0.016), atrial flutter (1.2% vs 0.0%, OR 31.1 (95% CI 4.3 
to 226.6), p=0.032) and eczema/dermatitis (7.0% vs 2.7%, OR 
2.7 (95% CI 1.2 to 6.2), p=0.028). Two conditions related to 
those previously reported in males with XLI were not reported 
significantly more frequently in male deletion carriers than male 
controls: ‘undescended testicle’ (0.0% vs 0.1%, p>0.99) and 
‘cataract’ (3.5% vs 1.6%, OR 2.3 (95% CI 0.7 to 7.2), p=0.15). 
No non- cancer illnesses we assessed were reported significantly 
more frequently in female deletion than female control subjects.
Mental health Questionnaire
Twenty- one male deletion and 95 female deletion carriers 
completed the MHQ, together with 58 855 male controls 
and 76 439 female controls. Male deletion carriers reported a 
significantly higher likelihood of having suffered mental distress 
preventing usual activities compared with male controls (57% vs 
26%, OR 3.8 (95% CI 1.6 to 9.0), p=0.003), but not a greater 
likelihood of having sought or received help for mental distress; 
female deletion carriers did not differ significantly from female 
controls on these measures (table 1). Mental health diagnoses 
reported in at least one male or female deletion carrier did 
not differ in frequency between deletion carriers and controls 
(table 1). No male or female deletion carriers reported having 
been diagnosed with any of the following conditions: schizo-
phrenia/other psychotic disorder, personality disorder, mania/
bipolar disorder, bulimia nervosa, psychological overeating/
binge eating, autism spectrum conditions, anorexia nervosa, 
agoraphobia or ADHD, and none of these conditions differed 
in frequency between deletion carriers and control subjects 
(p>0.99).
Responses to the remaining questions of the MHQ are 
presented in online supplementary tables 7 and 8. Male deletion 
carriers were more likely than male controls to have experienced 
‘recent easy annoyance or irritability’ (p<0.001) or to have ‘ever 
experienced a period of extreme irritability’ (p=0.031), and 
female deletion carriers were more likely than female controls 
to have experienced the former (p=0.018) (d≤0.02). Male dele-
tion carriers were significantly more likely than male controls 
to have experienced ‘prolonged feelings of sadness or depres-
sion’, ‘prolonged loss of interest in normal activities’ (OR 3.9 
(95% CI 1.4 to 10.6), p=0.009 and OR 3.5 (95% CI 1.5 to 
8.6), p=0.006, respectively) and ‘recent restlessness’ (p=0.008, 
d=0.012); we found weaker evidence for male deletion carriers 
being more affected than male controls by recent depression- 
related traits including: ‘feelings of inadequacy’ (p=0.039), 
‘trouble concentrating on things’ (p=0.011), ‘thoughts of 
suicide and self- harm’ (p=0.024) and ‘lack of interest or plea-
sure in doing things’ (p=0.015) (d<0.015). There was a nomi-
nally significantly increased prevalence of some anxiety- related 
traits in male deletion carriers relative to male controls, notably 
‘ever feeling worried, tense or anxious for most of a month or 
longer’ (OR 2.8 (95% CI 1.2 to 6.7), p=0.027). Male dele-
tion carriers did not differ from male controls with respect to 
traumatic event exposure, unusual/psychotic experiences, most 
aspects of alcohol use, cannabis use or happiness/well- being 
measures. Female deletion carriers differed from controls on 
some responses (0.01<p<0.05); notably, the former group were 
more likely to have experienced a period of mania/excitability 
(OR 2.5 (95% CI 1.2 to 5.1), p=0.02). Interestingly, both male 
and female deletion carriers reported consuming less alcohol 
than controls on a typical drinking day (p=0.013 and p=0.033, 
respectively, d≤0.02).
Medications
We found no difference in prescription rates for medications 
commonly used to treat heart arrhythmias (listed in online 
supplementary table 9) between male deletion carriers and 
male controls: male deletion (6/86, 7.0%) versus male controls 
(16 590/190 577, 8.7%) (χ2[1]=0.142, p=0.706). Nor did we 
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Table 2 Highest academic qualification achieved by male and female deletion carriers and controls
highest academic qualification
Male control 
(n=1 80 071)
Male deletion 
(n=78) statistical analysis
Female control 
(n=2 12 817)
Female 
deletion 
(n=290) statistical analysis
College/University degree 62 371 (35%) 18 (23%) P=0.083 67 798 (32%) 84 (29%) χ2[5]=3.995, p=0.550
A/AS Levels 19 794 (11%) 13 (17%) 27 229 (13%) 37 (13%)
O Levels/GCSEs 36 430 (20%) 21 (27%) 55 181 (26%) 75 (26%)
CSEs 10 424 (6%) 2 (2%) 12 550 (6%) 24 (8%)
NVQ/HND/HNC 17 684 (10%) 6 (8%) 10 100 (4%) 12 (4%)
None 33 368 (18%) 18 (23%) 39 959 (19%) 58 (20%)
Table 3 Performance on key measures of seven cognitive tasks by male and female deletion carriers and controls
Cognitive task Control group deletion group statistical comparison
benjamini- 
hochberg 
corrected p 
value
Male participants
Pairs Matching Test (total number of 
errors)
−0.11 (−0.11 to −0.11) (n=42 990) 0.25 (−0.11 to 0.54) (n=86) B=0.202±0.112, β=0.009, p=0.071 0.166
Reaction Time Test −0.19 (−0.19 to −0.18) (n=42 626) −0.025 (−0.19 to 0.265) (n=86) B=0.217±0.101, β=0.010, p=0.032 0.112
Fluid Intelligence Test (total number of 
correct answers)
0.40 (−0.07 to 0.40) (n=13 072) −0.07 (−0.55 to 0.40) (n=31) B=−0.465±0.190, β=−0.021, 
p=0.014
0.098
Digit Span Test (maximum number of 
digits remembered)
0.21 (0.21 to 0.21) (n=4195) 0.21 (−0.165 to 0.97) (n=10) U=18 543.5, p=0.512 0.563
Symbol Digit Substitution Test (number 
of correct substitutions)
0.05 (0.05 to 0.05) (n=11 664) −0.35 (−0.838 to 0.345) (n=13) U=63 851, p=0.323 0.452
Trail Making Test A (time to 
completion)
−0.19 (−0.22 to −0.17) (n=10 580) −0.04 (−0.43 to 1.07) (n=14) U=58 547, p=0.175 0.306
Trail Making Test B (time to 
completion)
−0.11 (−0.13 to −0.10) (n=10 588) 0.125 (−0.53 to 0.44) (n=14) U=67 499, p=0.563 0.563
Female participants
Pairs Matching Test (total number of 
errors)
−0.11 (−0.11 to −0.11) (n=54 151) 0.25 (−0.11 to 0.25) (n=312) B=0.105±0.057, β=0.008, p=0.067 0.235
Reaction Time Test 0.01 (0.01 to 0.01) (n=53 692) −0.10 (−0.24 to 0.0495) (n=309) B=−0.0202±0.052, β=−0.002, 
p=0.697
0.835
Fluid Intelligence Test (total number of 
correct answers)
−0.07 (−0.07 to −0.07) (n=16 615)
(mean: 0.05±0.0074)
−0.07 (−0.55 to −0.07) (n=103)
(mean: −0.31±0.0972)
B=−0.352±0.096, β=−0.028, 
p<0.001
<0.0063
Digit Span Test (maximum number of 
digits remembered)
0.21 (0.21 to 0.21) (n=5386) 0.21 (−0.54 to 0.59) (n=36) B=0.058±0.160, β=0.005, p=0.716 0.835
Symbol Digit Substitution Test (number 
of correct substitutions)
0.05 (0.05 to 0.05) (n=15 163) 0.15 (−0.25 to 0.54) (n=64) B=−0.063±0.114, β=−0.004, 
p=0.581
0.835
Trail Making Test A (time to 
completion)
−0.02 (−0.04 to 0.00) (n=13 179) 0.015 (−0.28 to 0.29) (n=58) B=0.020±0.126, β=0.001, p=0.875 0.875
Trail Making Test B (time to 
completion)
0.01 (−0.01 to 0.03) (n=13 206) 0.08 (−0.17 to 0.385) (n=58) B=0.123±0.121, β=0.009, p=0.307 0.716
Data are presented as median z- scores with 95% confidence limits.
find any evidence for differential prescription of medications 
commonly used to treat ADHD- related symptoms (online 
supplementary table 9): male deletion (0/86, 0%) versus male 
controls (14/190 577, 0%) (p>0.99) and female deletion (0/312, 
0%) versus female controls (11/227 862, 0%) (p>0.99). Finally, 
we found no evidence that prescription rates of medications 
used to treat mood symptoms (online supplementary table 9) 
differed across groups: male deletion (5/86, 5.8%) versus male 
controls (9419/190 577, 4.9%) (p=0.617) and female deletion 
(31/312, 9.9%) versus female controls (21 008/227 862, 9.2%) 
(χ2[1]=0.115, p=0.735).
Academic qualifications and cognitive function
Neither male deletion, nor female deletion, carriers differed 
from their respective controls with respect to highest academic 
qualification achieved (table 2). Male deletion subjects 
(57.5±0.8 years) and female deletion subjects (56.3±0.45 years) 
were compared with a subset of closely age- matched male 
(55–60 years, mean: 57.7±0.01 years) and female (55–60 years, 
mean: 57.7±0.01 years) control subjects on the cognitive tests. 
On average, male deletion carriers performed more poorly than 
male controls across all tasks, exhibiting significantly slower reac-
tion times in the Reaction Time Test (B=0.217±0.101, β=0.010, 
p=0.032), and providing significantly fewer correct answers in 
the  Fluid  Intelligence  Test  (B=−0.465±0.190,  β=−0.021, 
p=0.014); however, only the latter difference reached signifi-
cance after correcting for multiple testing (corrected p=0.098) 
(table 3). Female deletion carriers only demonstrated significantly 
different (worse) performance from female controls on the Fluid 
Intelligence Test (corrected p<0.0063, d=0.054) (table 3).
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Table 4 Volumes of eight subcortical brain regions (right and left hemisphere) in male and female deletion carriers and controls
hemisphere subcortical region
Volume in control 
female subjects (cm3) 
(n=415)
Volume in female 
deletion subjects (cm3) 
(n=14)
statistical 
comparison
Mann- Whitney u 
value, p value
benjamini- hochberg 
corrected p value
Left Lateral ventricle 7.62 (7.08 to 8.06) 9.32 (7.50 to 11.18) 2038, 0.059 0.189
Thalamus 7.15 (7.05 to 7.25) 7.17 (6.19 to 7.53) 2582.5, 0.480 0.640
Caudate 3.20 (3.17 to 3.24) 3.15 (2.91 to 3.21) 2347, 0.226 0.452
Putamen 4.84 (4.78 to 4.90) 4.44 (3.82 to 4.99) 1912, 0.030 0.120
Pallidum 1.23 (1.19 to 1.25) 1.15 (0.99 to 1.25) 2168.5, 0.106 0.283
Hippocampus 4.10 (4.05 to 4.15) 4.08 (3.79 to 4.51) 2823, 0.857 0.914
Amygdala 1.48 (1.45 to 1.50) 1.47 (1.30 to 1.57) 2676.5, 0.617 0.705
Nucleus accumbens 0.52 (0.50 to 0.53) 0.44 (0.40 to 0.49) 1668, 0.007 0.072
Right Lateral ventricle 7.17 (6.83 to 7.64) 8.57 (7.48 to 10.58) 2257, 0.159 0.363
Thalamus 6.28 (6.25 to 6.35) 6.11 (5.83 to 6.70) 2537, 0.420 0.611
Caudate 3.30 (3.26 to 3.36) 3.21 (3.04 to 3.44) 2462, 0.338 0.541
Putamen 4.64 (4.58 to 4.71) 4.31 (3.88 to 4.63) 1713, 0.009 0.072
Pallidum 1.40 (1.39 to 1.42) 1.31 (1.16 to 1.40) 1816.5, 0.019 0.101
Hippocampus 4.23 (4.20 to 4.27) 4.19 (3.97 to 4.60) 2903, 0.997 0.997
Amygdala 1.53 (1.51 to 1.55) 1.46 (1.37 to 1.76) 2635, 0.554 0.682
Nucleus accumbens 0.54 (0.53 to 0.55) 0.50 (0.45 to 0.60) 2460, 0.329 0.541
Data are presented as median values with 95% confidence limits.
subcortical neuroanatomy
Neuroimaging data were available for only two male deletion 
carriers hence analysis was limited to a comparison between 
female deletion carriers (n=14) and a subset of female controls 
(n=415) matched as closely as possible for handedness, scan-
ning centre, age at scanning (61.2±2.9 vs 61.0±0.04 years, 
respectively,  t[4.0]=−0.060,  p=0.955),  and  intracranial 
volume (1396±39 vs 1399±4 cm3, respectively, t[13.2]=0.074, 
p=0.942). Four subcortical brain regions were nominally signifi-
cantly smaller in deletion than control subjects (left and right 
putamen, right pallidum and left nucleus accumbens); two of 
these comparisons (right putamen and left nucleus accumbens) 
survived correction for multiple testing (corrected p=0.072, 
d=0.254 and d=0.264, respectively), while a third almost did 
(right pallidum, corrected p=0.101, d=0.232) (table 4).
dIsCussIon
We aimed to refine and extend the list of medical and neuro-
behavioural phenotypes linked to XLI- associated genetic muta-
tions using an approach arguably less prone to confounding than 
those undertaken previously. The prevalence of the mutation- 
of- interest in our sample was ~1/890 females, a figure consis-
tent with published estimates of 1/750–1200 based on prenatal 
screening data and mutation transmission rates.6 31 The preva-
lence of the mutation among males in our sample was ~1/2200, 
a figure slightly lower than the ~1/1500 estimate arising from 
prenatal screening in North American populations.32 33 Although 
the lower prevalence in our sample could reflect geographical 
genetic differences, it more likely reflects an ascertainment bias 
whereby some males with XLI- associated genetic deletions are 
not recruited into the UK Biobank; this could be due, in part, to 
psychological characteristics of this group.34 Our experimental 
strategy meant that individuals with small deletions or point 
mutations within STS would have been included in the non- 
deletion carrier ‘control’ group; however, the inclusion of these 
rare individuals would have negligible effects on the overall 
group score, and would likely act to reduce the magnitude of 
between- group effects.
Unsurprisingly, the prevalence of relevant skin phenotypes 
based on ICD-10 and self- report diagnostic data was signifi-
cantly higher in male deletion carriers relative to non- carriers. 
However,<6% of male deletion carriers reported a relevant 
diagnosis, implying that older STS- deficient individuals are only 
rarely being diagnosed with XLI. This may be because the derma-
tological manifestations of the condition are frequently mild with 
only more severe and/or visible cases recognised, and some cases 
could have been misdiagnosed as eczema/dermatitis.35 Within 
male deletion subjects, we found no evidence for increased rates 
of phenotypes most closely related to those previously suggested 
to be elevated in individuals with XLI (testicular maldescent and 
cataracts); given reliable existing data on an association between 
XLI and cryptorchidism in paediatric patients,1 the lack of asso-
ciation with testicular maldescent observed currently may be 
explained by an unwillingness or inability of older participants 
to self- report this condition.
We identified one robust novel medical phenotype, atrial fibril-
lation/flutter, presenting more commonly in male deletion carriers 
(10.5%) than in controls (2.7%); importantly, the prevalence rate 
of atrial fibrillation/flutter in our controls is comparable with that 
observed in epidemiological studies across Europe and the USA 
(2%–3%).36 Possible mechanism(s) underlying the relationship 
between XLI- associated mutations and heart arrhythmia are mani-
fold and might be investigated in experimentally tractable systems. 
It is noteworthy that XLI impacts on circulating DHEAS levels,37 38 
which have repeatedly been linked to atrial fibrillation in older 
men,39–41 and that paroxysmal supraventricular tachycardia has 
been noted in a young boy with XLI.42 DHEAS may feasibly influ-
ence atrial fibrillation through conversion to biologically active 
androgens and oestrogens, via vascular remodelling, or through 
its anti- inflammatory action.40 It is also of interest that microarray 
analysis has implicated reduced triadin expression in STS- deficient 
mouse tissues43 as, in man, the absence of cardiac triadin is associ-
ated with increased risk of arrhythmia.44 45 Although prescription 
rates for medication used to treat heart arrhythmias did not differ 
across groups, this might be explained by the fact that these medi-
cations are used to treat other conditions.
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We found no evidence that male or female deletion carriers 
differed from their respective controls in terms of rates of psychi-
atric/neurological diagnoses, and prescription rates for medications 
used to treat ADHD and mood disorders were equivalent across 
groups. However, these findings should be viewed in light of low 
levels of psychopathology within the UK Biobank sample,18 and 
in particular, the very low baseline rate of developmental disorder 
diagnoses. MHQ analysis revealed that both male and female dele-
tion carrier groups were affected by higher rates of irritability than 
their respective controls, an observation in line with our previous 
findings,6 12 and with elevated levels of aggression in STS- deficient 
mice.16 46 Male deletion carriers were more likely than male 
controls to report experiencing psychological distress and a variety 
of depressive and anxiety- related symptoms, and mood symptoms 
may be under- recognised within this group. The increased rate of 
depressive and anxiety- related traits in male deletion carriers is 
unlikely to be due to increased exposure to traumatic events, but 
may feasibly be related to having to live with a potentially stigma-
tising, lifelong skin condition; however, the fact that Sts- deficient 
mice exhibit anxiety- related traits16 suggests that biological influ-
ences contribute. Female deletion carriers showed some evidence 
for differences in mood symptoms from controls, but these differ-
ences were smaller in magnitude and less consistent in pattern/
direction than those observed for males, in accordance with the 
idea that female deletion carriers exhibit milder phenotypes than 
male deletion carriers.
Given data suggesting increased rates of ADHD3 9 10 and 
inattention in male12 and female6 deletion carriers, and atten-
tional abnormalities in STS- deficient mice,17 we anticipated 
group differences on attentionally demanding cognitive tasks. 
Although we did find some evidence that male deletion carriers 
exhibited slower reaction times than male controls on a simple 
stimulus- response task (consistent with impaired attention, 
reduced motor impulsivity and/or slower processing speed), the 
two groups did not differ on the Trail Making Tasks. This lack 
of effect could be explained by low power. We did find evidence 
across both male and female deletion groups for poorer perfor-
mance on the Fluid Intelligence Task, taxing multiple high- level 
cognitive skills; this performance deficit did not translate into 
impairments in academic performance.
We examined, for the first time, the effects of XLI- associated 
genetic mutations on neuroanatomy, although only in female 
carriers. Our analyses provide preliminary evidence for reduced 
right putamen and pallidum volume, and left accumbens volume, 
but no other subcortical structural changes, in deletion carriers 
relative to controls. We argue that these specific structural differ-
ences are genuine, and could partially explain effects on disorder 
risk/cognition/behaviour: a) STS is highly expressed in the basal 
ganglia during human neurodevelopment8 and adult STS- deficient 
male mice exhibit substantially altered striatal neurochemistry,47 
b) reduced volume of the putamen/nucleus accumbens is observed 
in idiopathic autism48 and ADHD49 cases (with reduced pallidum 
volume also seen in the former), c) adult basal ganglia volumes 
correlate with aspects of intelligence50 and this structure mediates 
attention/distractibility.51 Future functional neuroimaging studies 
in male and female deletion carriers might examine the extent 
to which the structure, function and neurochemistry of the basal 
ganglia correlates with behavioural and cognitive measures. As 
basal ganglia serotonergic (5- HT) function mediates attention, 
impulsivity and mood phenotypes (notably via 5- HT2A and 5- HT2C 
receptors)52 53 and is altered in STS- deficient mice,47 a particular 
focus on this system may be warranted.
In summary, this study has highlighted a novel medical pheno-
type coupled with XLI- associated mutations, has confirmed an 
excess of depression and anxiety- related traits in male carriers, 
and has, for the first time, identified cognitive and neuroana-
tomical correlates of these genetic differences. Our findings 
indicate that individuals with XLI might benefit from multidis-
ciplinary clinical care from dermatologists, psychiatrists, and 
cardiologists, and should lead to improved genetic counselling 
for patients and their families.
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